The Phase 2a "ZONE" study will evaluate the effect of ZT-01 on preventing nighttime hypoglycemia (low blood glucose) in people with Type 1 diabetes. Results of the Phase 1b proof-of-concept study were…
TIAP portfolio company Zucara Therapeutics moves their lead program targeting diabetes into Phase II clinical trials. Read more here. Why this news is important: Zucara has achieved the development milestones…
Zucara Therapeutics announced highly positive results from its proof-of-concept Phase 1b trial of ZT-01 in people with Type 1 diabetes (“T1D”). Please see the press release here. Why this news is important: This trial confirms ZT-01’s…
November 2, 2020: Zucara Therapeutics Inc., a diabetes life sciences startup funded by TIAP and adMare BioInnovations, announced today that it has received funding from NRC IRAP and MITAS for…
– Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials – – Series A Financing led by the Perceptive Xontogeny Venture Fund – TORONTO, March 31, 2020 (GLOBE…
Toronto & Vancouver, Canada: Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with type 1 diabetes and other types of insulin-dependent…
New paper published in The Lancet Diabetes & Endocrinology recommends exercise guidelines for type 1 diabetes patients and healthcare providers. Experts from JDRF, the leading global organization focused on type…
VANCOUVER and TORONTO, Canada (November 3, 2016) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, announced…
This new license is an important step forward in bringing a new drug therapy closer to patients living with diabetes as it will enable us to access a promising lead…
TORONTO and VANCOUVER, CANADA (January 12, 2016) — A novel drug therapy to reduce the severity and frequency of hypoglycemic (low blood sugar) episodes in people with diabetes is being…
MaRS Centre, West Tower
661 University Avenue, Suite 465
Toronto, ON M5G 1M1
info@tiap.ca